The glycine transporter 1 gene (GLYT1) is associated with methamphetamine-use disorder

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 147, Issue 1, 2008, Pages 54-58

  Morita, Yukitaka ^a   Ujike, Hiroshi ^a,b   Tanaka, Yuji ^a   Kishimoto, Makiko ^a   Okahisa, Yuko ^a   Kotaka, Tatsuya ^a   Harano, Mutsuo ^b,c   Inada, Toshiya ^b,d   Komiyama, Tokutaro ^b,e   Hori, Toru ^b,e   Yamada, Mitsuhiko ^b,e   Sekine, Yoshimoto ^b,f   Iwata, Nakao ^b,g   Iyo, Masaomi ^b,h   Sora, Ichiro ^b,i   Ozaki, Norio ^b,c   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Japanese Genetics Institute for Drug Abuse   (Japan)

^c Kurume University Graduate School of Medicine Kurume University Graduate School of Medicine Graduate School Biostatistics   (Japan)

^d TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Association study; Glycine transporter (GlyT); Substance dependence

Indexed keywords

GLYCINE TRANSPORTER 1; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG DEPENDENCE; FEMALE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GLYT1 GENE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANCE ABUSE; SYNAPSE;

ADULT; AMPHETAMINE-RELATED DISORDERS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 37849030451     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30565     Document Type: Article

References (41)

1. Adams RH, Sato K, Shimada S, Tohyama M, Puschel AW, Betz H. 1995. Gene structure and glial expression of the glycine transporter GlyT1 in embryonic and adult rodents. J Neurosci 15(3 Pt 2):2524-2532.
2. Bergeron R, Meyer TM, Coyle JT, Greene RW. 1998. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 95(26):15730-15734.
3. Bespalov A. 1996. The expression of both amphetamine-conditioned place preference and pentylenetetrazol-conditioned place aversion is attenuated by the NMDA receptor antagonist (+/-)-CPP. Drug Alcohol Depend 41(1):85-88.
4. Borowsky B, Mezey E, Hoffman BJ. 1993. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron 10(5):851-863.
5. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. 1997. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154(6):805-811.
6. Cervo L, Samanin R. 1995. Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain Res 673(2):242-250.
7. Chen L, Muhlhauser M, Yang CR. 2003. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 89(2):691-703.
8. Cubelos B, Gimenez C, Zafra F. 2005. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 15(4):448-459.
9. Depoortere R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, et al. 2005. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30(11):1963-1985.
10. Gabernet L, Pauly-Evers M, Schwerdel C, Lentz M, Bluethmann H, Vogt K, Alberati D, Mohler H, Boison D. 2005. Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression. Neurosci Lett 373(1):79-84.
11. Gomeza J, Ohno K, Betz H. 2003. Glycine transporter isoforms in the mammalian central nervous system: Structures, functions and therapeutic promises. Curr Opin Drug Discov Devel 6(5):675-682.
12. Harsing LG Jr, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M, et al. 2003. The glycine transporter-1 inhibitors NFPS and Org 24461: A pharmacological study. Pharmacol Biochem Behav 74(4):811-825.
13. Itokawa M, Yamada K, Yoshitsugu K, Toyota T, Suga T, Ohba H, Watanabe A, Hattori E, Shimizu H, Kumakura T, et al. 2003. A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 13(5):271-278.
14. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301-1308.
15. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. 2004. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29(2):300-307.
16. Johnson JW, Ascher P. 1987. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325(6104):529-531.
17. Kalivas PW, Stewart J. 1991. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 16(3):223-244.
18. Karler R, Calder LD, Chaudhry IA, Turkanis SA. 1989. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci 45(7):599-606.
19. Kim HS, Jang CG. 1997. MK-801 inhibits methamphetamine-induced conditioned place preference and behavioral sensitization to apomorphine in mice. Brain Res Bull 44(3):221-227.
20. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, Wittmann M, Lemaire W, Conn PJ. 2003. The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 23(20):7586-7591.
21. Laube B, Hirai H, Sturgess M, Betz H, Kuhse J. 1997. Molecular determinants of agonist discrimination by NMDA receptor subunits: Analysis of the glutamate binding site on the NR2B subunit. Neuron 18(3):493-503.
22. Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N. 1993. Cloning and expression of a spinal cord- and brain-specific glycine transporter with novel structural features. J Biol Chem 268(30):22802-22808.
23. Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, Bergeron R. 2004. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 557(Pt 2):489-500.
24. Mattick JS, Makunin IV. 2006. Non-coding RNA. Hum Mol Genet 15 Spec No LR17-R29.
25. McBride WJ, Murphy JM, Ikemoto S. 1999. Localization of brain reinforcement mechanisms: Intracranial self-administration and intracranial place-conditioning studies. Behav Brain Res 101(2):129-152.
26. Mead AN, Stephens DN. 1999. CNQX but not NBQX prevents expression of amphetamine-induced place preference conditioning: A role for the glycine site of the NMDA receptor, but not AMPA receptors. J Pharmacol Exp Ther 290(1):9-15.
27. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. 2001. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilonl subunit. J Neurosci 21(2):750-757.
28. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98(4):427-436.
29. Papp M, Gruca P, Willner P. 2002. Selective blockade of drug-induced place preference conditioning by ACPC, a functional NDMA-receptor antagonist. Neuropsychopharmacology 27(5):727-743.
30. Sato K, Adams R, Betz H, Schloss P. 1995. Modulation of a recombinant glycine transporter (GLYT1b) by activation of protein kinase C. J Neurochem 65(5):1967-1973.
31. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL. 1992. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8(5):927-935.
32. Tatetsu S. 1963. Methamphetamine psychosis. Folia Psychiatr Neurol Jpn (Suppl 7):377-380.
33. Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, Jiang Z, Caine SB, Coyle JT. 2004. Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype. Proc Natl Acad Sci USA 101(22):8485-8490.
34. Ujike H. 2002. Stimulant-induced psychosis and schizophrenia: The role of sensitization. Curr Psychiatry Rep 4:177-184.
35. Ujike H, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, Sora I, Iyo M, Katsu T, Nomura A, et al. 2003. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J 3(4):242-247.
36. Ujike H, Sato M. 2004. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 1025:279-287.
37. Vezina P, Queen AL. 2000. Induction of locomotor sensitization by amphetamine requires the activation of NMDA receptors in the rat ventral tegmental area. Psychopharmacology (Berl) 151(2-3):184-191.
38. Wolf ME. 1998. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54(6):679-720.
39. Wolf ME, Dahlin SL, Hu XT, Xue CJ, White K. 1995. Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: Comparison with N-metyl-D-aspartate antagonists. Neuroscience 69(2):417-439.
40. Zafra F, Gomeza J, Olivares L, Aragon C, Gimenez C. 1995. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci 7(6):1342-1352.
41. Zhao X, Li H, Shi Y, Tang R, Chen W, Liu J, Feng G, Shi J, Yan L, Liu H, et al. 2006. Significant association between the genetic variations in the 5′ end of the N-methyl-D-aspartate receptor subunit gene GRIN1 and schizophrenia. Biol Psychiatry 59(8):747-753.